Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease

BACKGROUND: In the OPTIMIZE study, 4 weeks of roflumilast 250 µg once daily before escalation to the approved 500 µg once daily maintenance dose reduced treatment discontinuations and improved tolerability to roflumilast among patients with chronic obstructive pulmonary disease (COPD). In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Facius, Axel, Marostica, Eleonora, Gardiner, Philip, Watz, Henrik, Lahu, Gezim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028881/
https://www.ncbi.nlm.nih.gov/pubmed/29797235
http://dx.doi.org/10.1007/s40262-018-0671-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028881/
https://www.ncbi.nlm.nih.gov/pubmed/29797235
http://dx.doi.org/10.1007/s40262-018-0671-4

Ejemplares similares